Billingham M S, Hall R A, Simpson S, Bailey C J
Diabete Metab. 1981 Dec;7(4):271-4.
A possible influence of oral hypoglycaemic drugs on plasma high density lipoprotein cholesterol (HDL-C) concentrations was examined in streptozotocin diabetic and non-diabetic mice. Treatment of streptozotocin diabetic mice with glibenclamide (0.4 mg/kg/day), chlorpropamide (10 mg/kg/day) or metformin (60 mg/kg/day) for 28 weeks did not significantly alter plasma total cholesterol (TC) or HDL-C in streptozotocin diabetic mice. Plasma TC and HDL-C were not related to the prevailing plasma glucose concentration. Non-diabetic mice treated with glibenclamide or metformin for 46 weeks showed no changes in TC or HDL-C. However, chlorpropamide increased TC and HDL-C, and lowered the TC : HDL-C molar ration after 46 weeks in non-diabetic mice. The effect of chlorpropamide was associated with an excessive gain in weight.
在链脲佐菌素诱导的糖尿病小鼠和非糖尿病小鼠中，研究了口服降糖药对血浆高密度脂蛋白胆固醇（HDL-C）浓度的可能影响。用格列本脲（0.4毫克/千克/天）、氯磺丙脲（10毫克/千克/天）或二甲双胍（60毫克/千克/天）治疗链脲佐菌素诱导的糖尿病小鼠28周，并未显著改变链脲佐菌素诱导的糖尿病小鼠的血浆总胆固醇（TC）或HDL-C。血浆TC和HDL-C与当时的血浆葡萄糖浓度无关。用格列本脲或二甲双胍治疗46周的非糖尿病小鼠，其TC或HDL-C没有变化。然而，氯磺丙脲在治疗46周后增加了非糖尿病小鼠的TC和HDL-C，并降低了TC:HDL-C摩尔比。氯磺丙脲的这种作用与体重过度增加有关。
